<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04228822</url>
  </required_header>
  <id_info>
    <org_study_id>201911121</org_study_id>
    <nct_id>NCT04228822</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility of a Low Carbohydrate Diet in Children With Type 1 Diabetes</brief_title>
  <official_title>Safety and Feasibility of a Low Carbohydrate Diet in Children With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICTS BJH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Diabetes Translation Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Good glycemic control in individuals with Type 1 diabetes (T1D), has been proven to reduce&#xD;
      the risk of diabetes-related complications. Despite technological advances such as the use of&#xD;
      insulin delivery devices and continuous glucose monitoring, the average glycemic control in&#xD;
      T1D is poor. Though dietary management plays a major role in the overall management of T1D,&#xD;
      and it is often classified as the most challenging aspect of treatment, the 2019 Standards of&#xD;
      Medical Care in Diabetes for children and adolescents do not clearly address dietary&#xD;
      management. As carbohydrate is the macronutrient with the greatest impact on blood glucose,&#xD;
      it is reasonable to suggest that carbohydrate reduction will minimize postprandial glucose&#xD;
      excursions and improve diabetes control. For this reason, low carbohydrate diets (LCD) have&#xD;
      gained popularity, and observational studies report positive glycemic outcomes. However, to&#xD;
      date, scientific evidence from randomized trials on the impact of LCD in children with T1D is&#xD;
      lacking. Thus, the over-arching goal of this pilot study is to evaluate the feasibility and&#xD;
      safety of a low carbohydrate diet in children with T1D, and as an exploratory aim, we will&#xD;
      evaluate the efficacy of LCD on glycemic control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators aim to study 40 subjects ages 5-11 with T1D to evaluate the feasibility of&#xD;
      LCD. Participants will be asked to attend a total of 5 visits (4 in person and 1 phone visit)&#xD;
      during the 6 month-duration of the study. Participants will be randomized to an intervention&#xD;
      group with a LCD (50% of carbohydrate recommended daily allowance) vs. the standard diet.&#xD;
&#xD;
      During the screening visit, participants will be assessed by a dietitian to categorize their&#xD;
      existing dietary regimen before randomization to either the LCD or the standard diet. In&#xD;
      addition, participant's insulin regimen (either pump settings or multiple dose insulin&#xD;
      injection therapy) will be reviewed for insulin dose adjustments as needed over a 2&#xD;
      week-period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>20 participants will be randomized to the intervention group (low carbohydrate diet) and 20 participants will be randomized to the control group</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of hypoglycemic events</measure>
    <time_frame>6 month study period</time_frame>
    <description>Using a continuous glucose monitor (CGM) and home glucose meter, investigators will calculate the number of hypoglycemic events (glucose values &lt;70 mg/dL but ≥ 54 mg/dL and those &lt;54 mg/dL), number of severe hypoglycemia and time spent in hypoglycemia (values &lt;70 mg/dL but ≥ 54 mg/dL and &lt;54 mg/dL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Episodes of diabetes related visits to the hospital, DKA</measure>
    <time_frame>6 month study period</time_frame>
    <description>Investigators will obtain data prospectively from medical records and will estimate the frequency of DKA, diabetes related hospitalizations / emergency department visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dyslipidemia</measure>
    <time_frame>6 month study period</time_frame>
    <description>Investigators will evaluate the changes in LDL levels among the study groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemic control</measure>
    <time_frame>6 month duration of the study</time_frame>
    <description>Investigators will evaluate the changes in glycemic control among the groups using HbA1c at baseline, 3 and 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose variability</measure>
    <time_frame>6 month study period</time_frame>
    <description>Using CGM data investigators will evaluate glucose variability using standard deviation (SD) of all glucose values. Secondary endpoints will include time of the day spent in range (values between 70-140 mg/dl and between 70 and 180mg/dl), in hypoglycemia (values &lt;70 mgl/dl but ≥ 54 mg/dl and &lt;54 mg/dl) and in hyperglycemia (values &gt;180mg/dl and &gt;250 mg/dl).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Low carb diet intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low carbohydrate diet defined as 25-35% of total energy intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard diet defined as 45-65% total energy intake</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low carbohydrate diet</intervention_name>
    <description>25-35% of carbohydrates from total energy intake</description>
    <arm_group_label>Low carb diet intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 5-11 years of age, with history of Type 1 diabetes for longer than 2 years,&#xD;
&#xD;
          -  No carbohydrate restrictions at the time of recruitment.&#xD;
&#xD;
          -  No medications that could affect appetite&#xD;
&#xD;
          -  Regular attendance at the clinic (3-4 times per year),&#xD;
&#xD;
          -  Glycated hemoglobin (HbA1c) &lt;10%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Impaired renal or liver function,&#xD;
&#xD;
          -  Chronic seizures or global developmental delay,&#xD;
&#xD;
          -  Diagnosed with ADHD and/or on ADHD medications&#xD;
&#xD;
          -  Use of drugs other than insulin affecting glucose metabolism&#xD;
&#xD;
          -  Severe eczema&#xD;
&#xD;
          -  Celiac disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ana Marie Arbelaez Perez, MD</last_name>
    <phone>314-454-6051</phone>
    <email>aarbelaez@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lucy Levandoski, PA-C</last_name>
    <phone>314-286-1101</phone>
    <email>levandoski_l@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucy Levandoski, PA-C</last_name>
      <phone>314-286-1101</phone>
      <email>levandoski_l@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Granados, MD</last_name>
      <phone>3144546051</phone>
      <email>agranados@wustl.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 11, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

